The effect of phenobarbital treatment on behavioral comorbidities and on the composition and function of the fecal microbiome in dogs with idiopathic epilepsy
Authors:
Open Access
- 4 August 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 9, 933905
Abstract
Phenobarbital (PB) is one of the most important antiseizure drugs (ASDs) to treat canine idiopathic epilepsy (IE). The effect of PB on the taxonomic changes in gastrointestinal microbiota (GIM) and their functions is less known, which may explain parts of its pharmacokinetic and pharmacodynamic properties, especially its antiseizure effect and drug responsiveness or drug resistance as well as its effect on behavioral comorbidities. Fecal samples of 12 dogs with IE were collected prior to the initiation of PB treatment and 90 days after oral PB treatment. The fecal samples were analyzed using shallow DNA shotgun sequencing, real-time polymerase chain reaction (qPCR)-based dysbiosis index (DI), and quantification of short-chain fatty acids (SCFAs). Behavioral comorbidities were evaluated using standardized online questionnaires, namely, a canine behavioral assessment and research questionnaire (cBARQ), canine cognitive dysfunction rating scale (CCDR), and an attention deficit hyperactivity disorder (ADHD) questionnaire. The results revealed no significant changes in alpha and beta diversity or in the DI, whereas only the abundance of Clostridiales was significantly decreased after PB treatment. Fecal SCFA measurement showed a significant increase in total fecal SCFA concentration and the concentrations of propionate and butyrate, while acetate concentrations revealed an upward trend after 90 days of treatment. In addition, the PB-Responder (PB-R) group had significantly higher butyrate levels compared to the PB-Non-Responder (PB-NR) group. Metagenomics of functional pathway genes demonstrated a significant increase in genes in trehalose biosynthesis, ribosomal synthesis, and gluconeogenesis, but a decrease in V-ATPase-related oxidative phosphorylation. For behavioral assessment, cBARQ analysis showed improvement in stranger-directed fear, non-social fear, and trainability, while there were no differences in ADHD-like behavior and canine cognitive dysfunction (CCD) scores after 90 days of PB treatment. While only very minor shifts in bacterial taxonomy were detected, the higher SCFA concentrations after PB treatment could be one of the key differences between PB-R and PB-NR. These results suggest functional changes in GIM in canine IE treatment.Keywords
This publication has 92 references indexed in Scilit:
- The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brainJournal of Neurochemistry, 2009
- Transport, Solute2009
- Clinical presentation of anxiety among patients with epilepsyNeuropsychiatric Disease and Treatment, 2008
- The metabolism of phenobarbital, a drug used for epilepsy, by intestinal flora, Bifidobacterium adolescentis and Bifidobacterium bifidumMicrobial Ecology in Health and Disease, 2006
- Initiation of Protein Synthesis in BacteriaMicrobiology and Molecular Biology Reviews, 2005
- Simultaneous measurement of plasma concentrations and 13C-enrichment of short-chain fatty acids, lactic acid and ketone bodies by gas chromatography coupled to mass spectrometryJournal of Chromatography B, 2003
- Anti‐inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL‐12 and up‐regulation of IL‐10 productionThe FASEB Journal, 2000
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000
- Physiological and Anti‐Inflammatory Roles of Dietary Fiber and Butyrate in Intestinal FunctionsJournal of Parenteral and Enteral Nutrition, 1999
- Review article: short chain fatty acids in health and diseaseAlimentary Pharmacology & Therapeutics, 1998